Effective on November 20, 2019, Gary Augusta, who was appointed as a member of the Board of Directors of Trxade Group, Inc. on October 9, 2019, resigned as a member of the Board of Directors. Mr. Augusta will be actively participating in the Company’s planned Nasdaq Capital Market uplisting process and as such, it was determined that he will likely not fit within the definition of an independent director under applicable Nasdaq Capital Market rules. Mr. Augusta did not serve on any Committees of the Board of Directors prior to his resignation. Effective on November 20, 2019, the Board of Directors of the Company appointed Dr. Pamela Tenaerts as a member of the Board of Directors to fill the vacancy created by Mr. Augusta’s resignation, pursuant to the power provided to the Board of Directors by the Bylaws of the Company and Delaware law. The Board of Directors also affirmatively determined that Dr. Tenaerts was “independent” under Nasdaq Capital Market rules and guidance. Dr. Tenaerts was appointed to the Audit Committee of the Board of Directors in connection with her appointment to the Board of Directors. Since May 2012, Dr. Tenaerts has served as the Executive Director of the Clinical Trials Transformation Initiative (CTTI), located at Duke University, where she works closely with the Executive Committee to develop and implement strategies to accomplish CTTI’s mission. On November 20, 2019, the Board of Directors of the Company formed a Nominating and Corporate Governance Committee and adopted a charter of the Nominating and Corporate Governance Committee. On the same date, the Board of Directors appointed Mr. Donald G. Fell (Chairman) and Mr. Michael L. Peterson, as members of the Nominating and Corporate Governance Committee.
TRxADE Health, Inc. provides a technology-enabled health services platform. The Company is focused on digitalizing the retail pharmacy and health services experience by optimizing drug procurement, the prescription journey, access to physicians in the patientâs home and patient engagement in the United States. The Companyâs segments include Trxade, Inc., Integra Pharma Solutions, LLC (IPS) and Superlatus. Trxade, Inc. segment provides a web-based pharmaceutical marketplace platform-business to business (B2B) sales. IPS is a licensed pharmaceutical wholesaler and sells brand, generic and non-drug products to customers. The Superlatus segment holds Sapientiaâs intellectual property for advanced food extrusion technology and The Urgent Company, which is a manufacturer of ice cream that is animal product-free, vegan, lactose-free, and made with plant-B2B sales. Its subsidiaries include Community Specialty Pharmacy, LLC, Alliance Pharma Solutions, LLC, Bonum Health, LLC and others.
TRXADE HEALTH, INC. 
